Skip to main content
. 2017 Jun 29;73(10):1315–1322. doi: 10.1007/s00228-017-2289-0

Fig. 1.

Fig. 1

Adjusted odds ratios (aOR) of factors associated with treatment decisions for a ASA compared to an oral anticoagulant, b warfarin compared to a NOAC, c dabigatran compared to apixaban and rivaroxaban, d rivaroxaban compared to dabigatran and apixaban, and e apixaban compared to dabigatran and rivaroxaban. Three multivariate models were used to calculate how stroke risk, bleeding risk, and age group influenced treatment decisions